Your browser doesn't support javascript.
loading
CSN6 drives carcinogenesis by positively regulating Myc stability.
Chen, Jian; Shin, Ji-Hyun; Zhao, Ruiying; Phan, Liem; Wang, Hua; Xue, Yuwen; Post, Sean M; Ho Choi, Hyun; Chen, Jiun-Sheng; Wang, Edward; Zhou, Zhongguo; Tseng, Chieh; Gully, Christopher; Velazquez-Torres, Guermarie; Fuentes-Mattei, Enrique; Yeung, Giselle; Qiao, Yi; Chou, Ping-Chieh; Su, Chun-Hui; Hsieh, Yun-Chih; Hsu, Shih-Lan; Ohshiro, Kazufumi; Shaikenov, Tattym; Wang, Huamin; Yeung, Sai-Ching Jim; Lee, Mong-Hong.
Afiliação
  • Chen J; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Shin JH; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Zhao R; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Phan L; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Wang H; Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Xue Y; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Post SM; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Ho Choi H; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Chen JS; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Wang E; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Zhou Z; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Tseng C; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Gully C; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Velazquez-Torres G; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Fuentes-Mattei E; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Yeung G; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Qiao Y; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Chou PC; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Su CH; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Hsieh YC; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Hsu SL; Department of Education and Research, Taichung Veterans General Hospital, No. 160, Section 3, Chung-Gang Road, Taichung, 40705 Taiwan, ROC.
  • Ohshiro K; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Shaikenov T; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Wang H; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Yeung SC; 1] Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Lee MH; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Nat Commun ; 5: 5384, 2014 Nov 14.
Article em En | MEDLINE | ID: mdl-25395170
Cullin-RING ubiquitin ligases (CRLs) are critical in ubiquitinating Myc, while COP9 signalosome (CSN) controls neddylation of Cullin in CRL. The mechanistic link between Cullin neddylation and Myc ubiquitination/degradation is unclear. Here we show that Myc is a target of the CSN subunit 6 (CSN6)-Cullin signalling axis and that CSN6 is a positive regulator of Myc. CSN6 enhanced neddylation of Cullin-1 and facilitated autoubiquitination/degradation of Fbxw7, a component of CRL involved in Myc ubiquitination, thereby stabilizing Myc. Csn6 haplo-insufficiency decreased Cullin-1 neddylation but increased Fbxw7 stability to compromise Myc stability and activity in an Eµ-Myc mouse model, resulting in decelerated lymphomagenesis. We found that CSN6 overexpression, which leads to aberrant expression of Myc target genes, is frequent in human cancers. Together, these results define a mechanism for the regulation of Myc stability through the CSN-Cullin-Fbxw7 axis and provide insights into the correlation of CSN6 overexpression with Myc stabilization/activation during tumorigenesis.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeo Hidrolases / Proteínas Proto-Oncogênicas c-myc / Proteínas Adaptadoras de Transdução de Sinal / Carcinogênese Idioma: En Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeo Hidrolases / Proteínas Proto-Oncogênicas c-myc / Proteínas Adaptadoras de Transdução de Sinal / Carcinogênese Idioma: En Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Estados Unidos